EPS for Progenics Pharmaceuticals, Inc. (PGNX) Expected At $-0.23; 16 Analysts Bullish Skechers U.S.A., Inc. (SKX)

April 17, 2018 - By wolcottdaily

Skechers U.S.A., Inc. (NYSE:SKX) Logo

Among 19 analysts covering Skechers Usa Inc. (NYSE:SKX), 16 have Buy rating, 0 Sell and 3 Hold. Therefore 84% are positive. Skechers Usa Inc. had 66 analyst reports since July 22, 2015 according to SRatingsIntel. The company was maintained on Tuesday, February 6 by B. Riley & Co. The stock of Skechers U.S.A., Inc. (NYSE:SKX) earned “Equal-Weight” rating by Morgan Stanley on Friday, October 20. Cowen & Co upgraded the stock to “Outperform” rating in Friday, March 24 report. The stock of Skechers U.S.A., Inc. (NYSE:SKX) has “Neutral” rating given on Friday, January 22 by Susquehanna. The stock has “Buy” rating by B. Riley & Co on Friday, October 20. The stock of Skechers U.S.A., Inc. (NYSE:SKX) earned “Buy” rating by Cowen & Co on Monday, August 14. The stock of Skechers U.S.A., Inc. (NYSE:SKX) has “Neutral” rating given on Friday, July 22 by Monness Crespi & Hardt. Wedbush initiated it with “Neutral” rating and $23 target in Wednesday, November 2 report. The stock has “Buy” rating by Monness Crespi & Hardt on Friday, December 23. Wedbush maintained the stock with “Hold” rating in Friday, July 21 report. See Skechers U.S.A., Inc. (NYSE:SKX) latest ratings:

13/04/2018 Broker: Susquehanna Rating: Buy New Target: $52.0000 Maintain
09/02/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $45 New Target: $50 Maintain
08/02/2018 Broker: Cowen & Co Rating: Buy New Target: $46.0 Maintain
06/02/2018 Broker: B. Riley & Co Old Rating: Buy New Rating: Buy Old Target: $37 New Target: $47 Maintain
06/02/2018 Broker: FBR Capital Rating: Buy New Target: $47.0 Maintain
09/01/2018 Broker: Susquehanna Rating: Buy New Target: $46.0 Maintain
03/01/2018 Broker: Wedbush Rating: Buy New Target: $45.0 Maintain
15/12/2017 Broker: Argus Research Old Rating: Hold New Rating: Buy Upgrade
01/12/2017 Broker: Monness Crespi Rating: Buy Old Target: $34.00 New Target: $40.00 Maintain
20/10/2017 Broker: Monness Crespi Rating: Buy Old Target: $33.00 New Target: $34.00 Maintain

Analysts expect Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report $-0.23 EPS on May, 3.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.23 EPS. After having $-0.21 EPS previously, Progenics Pharmaceuticals, Inc.’s analysts see 9.52% EPS growth. The stock increased 0.83% or $0.06 during the last trading session, reaching $7.32. About 325,837 shares traded. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has declined 32.66% since April 17, 2017 and is downtrending. It has underperformed by 44.21% the S&P500.

Investors sentiment increased to 1.34 in Q4 2017. Its up 0.07, from 1.27 in 2017Q3. It increased, as 25 investors sold Skechers U.S.A., Inc. shares while 86 reduced holdings. 76 funds opened positions while 73 raised stakes. 110.47 million shares or 8.33% more from 101.97 million shares in 2017Q3 were reported. Prudential has invested 0.13% in Skechers U.S.A., Inc. (NYSE:SKX). Jpmorgan Chase And has invested 0% of its portfolio in Skechers U.S.A., Inc. (NYSE:SKX). Shelton Capital Management owns 10,259 shares or 0.02% of their US portfolio. Parametric Port Associates Ltd Com reported 530,936 shares or 0.02% of all its holdings. 206,510 are owned by Cornerstone Cap Mngmt Holdings Ltd Liability Com. Janney Montgomery Scott reported 0.02% of its portfolio in Skechers U.S.A., Inc. (NYSE:SKX). Liberty Mutual Group Asset owns 33,988 shares. Buckingham Cap Mngmt reported 414,532 shares. Earnest Ptnrs Ltd Limited Liability Company owns 55 shares. Trexquant Inv L P stated it has 0.08% of its portfolio in Skechers U.S.A., Inc. (NYSE:SKX). Quantbot Tech Ltd Partnership owns 35,171 shares or 0.12% of their US portfolio. Raymond James And Associate holds 0% of its portfolio in Skechers U.S.A., Inc. (NYSE:SKX) for 46,708 shares. Balyasny Asset Ltd Co owns 1.24M shares. Morgan Stanley has invested 0.01% in Skechers U.S.A., Inc. (NYSE:SKX). Raymond James Finance Advsr invested 0.01% in Skechers U.S.A., Inc. (NYSE:SKX).

Since October 24, 2017, it had 0 buys, and 7 insider sales for $4.79 million activity. 4,000 shares were sold by Erlich Morton D, worth $134,620. On Wednesday, February 28 the insider NASON MARK A sold $6,552. The insider PACCIONE PHILLIP sold $663,113. Shares for $851,700 were sold by SISKIND RICHARD on Tuesday, October 24. WEINBERG DAVID also sold $935,158 worth of Skechers U.S.A., Inc. (NYSE:SKX) on Friday, March 2. GREENBERG ROBERT also sold $1.53 million worth of Skechers U.S.A., Inc. (NYSE:SKX) shares.

Skechers U.S.A., Inc. designs, develops, markets, and distributes footwear for men, women, and children; and performance footwear for men and women under the Skechers GO brand worldwide. The company has market cap of $6.81 billion. It operates through three divisions: Domestic Wholesale Sales, International Wholesale Sales, and Retail Sales. It has a 37.33 P/E ratio. The firm offers casual boots, shoes, and sandals for men; oxfords and slip-ons, lug outsole and fashion boots, and casual sandals for women; dress casuals, seasonal sandals and boots, classic and wide fit, and relaxed fit casuals for men and women; and casual fusion line for young men and women under the Skechers USA brand.

The stock increased 0.37% or $0.1567 during the last trading session, reaching $42.5567. About 526,974 shares traded. Skechers U.S.A., Inc. (NYSE:SKX) has risen 33.31% since April 17, 2017 and is uptrending. It has outperformed by 21.76% the S&P500.

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company has market cap of $531.89 million. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen -targeted positron emission topography (PET) imaging agent for prostate cancer. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products.

Among 5 analysts covering Progenics Pharm (NASDAQ:PGNX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Progenics Pharm had 11 analyst reports since August 6, 2015 according to SRatingsIntel. On Wednesday, August 9 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The rating was maintained by Needham with “Buy” on Tuesday, June 20. On Monday, February 6 the stock rating was upgraded by Needham to “Strong Buy”. The firm has “Buy” rating by Jefferies given on Tuesday, September 26. The rating was downgraded by Zacks to “Buy” on Friday, August 7. The company was maintained on Thursday, August 6 by Brean Capital. The firm has “Buy” rating given on Friday, August 7 by Needham. The company was maintained on Thursday, June 8 by Jefferies. The firm earned “Buy” rating on Thursday, October 27 by Aegis Capital. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has “Buy” rating given on Friday, October 23 by Jefferies.

Investors sentiment increased to 1.22 in Q4 2017. Its up 0.11, from 1.11 in 2017Q3. It increased, as 11 investors sold Progenics Pharmaceuticals, Inc. shares while 40 reduced holdings. 22 funds opened positions while 40 raised stakes. 56.89 million shares or 3.42% less from 58.90 million shares in 2017Q3 were reported. Invesco Ltd owns 189,618 shares for 0% of their portfolio. Ameriprise Inc holds 0% or 360,809 shares in its portfolio. Thrivent Financial For Lutherans reported 43,263 shares or 0% of all its holdings. Virginia Retirement System Et Al reported 34,200 shares or 0% of all its holdings. Millennium Mngmt Ltd Liability has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Westwood Mgmt Corp Il owns 12,000 shares for 0.01% of their portfolio. Mufg Americas Hldg has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Rice Hall James & Associates Ltd Company invested 0.32% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Swiss Bancshares holds 115,700 shares. Cadence Ltd Co stated it has 260,046 shares or 0.1% of all its holdings. Phocas Fincl reported 0.72% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Blair William Il stated it has 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Ubs Asset Americas owns 39,549 shares for 0% of their portfolio. Kbc Gru Nv has 0.01% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 217,572 shares. Northern Trust, Illinois-based fund reported 875,841 shares.

Skechers U.S.A., Inc. (NYSE:SKX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 wolcottdaily

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: